Sign In
Buy OPT
$3.41
+0 (+0%)
At Close: Jun 30, 2025
Opthea Company Secretary Resignation
05:30am, Tuesday, 06'th Apr 2021
MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of the
Opthea Receives FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD
05:30am, Wednesday, 31'st Mar 2021
MELBOURNE, Australia, March 31, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progr
Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMD
05:30am, Monday, 15'th Mar 2021
MELBOURNE, Australia, March 15, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and prog
Opthea to Present at the Oppenheimer 31st Annual Healthcare Conference
05:30am, Wednesday, 10'th Mar 2021
MELBOURNE, Australia, March 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and prog
Opthea Finalizes Study Designs and Start-up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD
05:30am, Wednesday, 24'th Feb 2021
MELBOURNE, Australia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progr
Opthea to Present at the 10th Annual SVB Leerink Global Healthcare Conference
05:30am, Wednesday, 17'th Feb 2021
MELBOURNE, Australia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progr
